LKFT logo

LKFT Lakefront Biotherapeutics N.V.

NASDAQ Global Select · Biotechnology · Healthcare

$33.93
-0.14 (-0.41%)

Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in …

Market Cap: $2.22Blakefrontbio.com

Price

No data yet.

Social Signal Score

39
5d
40
2 mentions
—
30d
30
4 mentions
—
60d
42
8 mentions
—
90d
45
13 mentions
—
news: 13

Analyst Ratings

2 analysts
Buyconsensus
Strong Buy 0Buy 1Hold 1Sell 0Strong Sell 0
Avg price target$35.5+4.6%
Low $26Median $35.5High $45
Current Consensus

Revenue

$7.53M-88.27%
$-209.12M$160.86M$530.84M$900.82M
Sep 2021Sep 2026

Analyst Estimates

FY2025
$-6.41
$-12.97–$-2.83
1 analysts
FY2026
$-1.86
$-6.61–$1.41
2 analysts
FY2027
$-2.55
$-3.89–$-0.82
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Henry Gosebruch
Sector
Healthcare
Industry
Biotechnology
Employees
452
Beta
0.12
Country
BE
Piotroski score
5 / 9 (Middling)
Altman Z-score
21.20
lakefrontbio.com